Prior to the COVID-19 pandemic, NCI estimated that about 3% to 5% of adult cancer patients participated in clinical trials.

Despite the many advances in oncology, important problems continue to beset the field, including rapidly rising costs, uneven patterns of care, and poor access to (and participation in) cancer trials. A model that has been recently developed and tested to address these issues is the so-called academic hybrid community cancer center.